ASPIRE-GCT: a phase II trial protocol of aspirin thromboprophylaxis during chemotherapy for advanced germ cell tumors

Advanced germ cell tumors (GCT) are highly curable with cisplatin-based chemotherapy; however, patients with advanced GCT are at high risk for venous thromboembolism (VTE) during treatment, and the role of thromboprophylaxis is not established. Low-dose aspirin (acetylsalicylic acid [ASA]) is inexpensive, widely available, and reduces VTE risk in orthopedic trauma, arthroplasty, and multiple myeloma settings. ASPIRE-GCT is an investigator-initiated, single-arm, prospective phase II study evaluating the 6-month VTE-free rate in patients with advanced GCT at high VTE risk who receive standard cisplatin-based chemotherapy plus ASA 81 mg daily for 26 weeks. Eligible patients are males aged 18–70 years with stage IS or higher testicular, mediastinal, or retroperitoneal GCT planned for three to four cycles of cisplatin-based chemotherapy and at least one high-risk feature: AJCC stage IIC/III or higher or Khorana score ≥2. The primary endpoint is 6-month VTE-free rate. A Simon two-stage design will enroll 13 evaluable participants in stage one and up to 31 overall. Secondary endpoints include major and clinically relevant non-major bleeding, relapse-free survival, and overall survival.Clinical trial registration www.clinicaltrials.gov identifier is NCT06866964; registered 4 March 2025; Protocol version: Version 4: 11/13/2025.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-11-14
DOI
https://doi.org/10.1080/14796694.2026.2759456
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ASPIRE-GCT: a phase II trial protocol of aspirin thromboprophylaxis during chemotherapy for advanced germ cell tumors

Landon Carter Brown, Earle Frederick Burgess, Michael Joseph McCormack, James Thomas Symanowski et al.
Future Oncology
Venous Thromboembolism Diagnosis and Management
article

ASPIRE-GCT: a phase II trial protocol of aspirin thromboprophylaxis during chemotherapy for advanced germ cell tumors

Landon Carter Brown, Earle Frederick Burgess, Michael Joseph McCormack, James Thomas Symanowski, Antony Ruggeri, Claud M. Grigg, Jason Zhu, Sarah Norek, Ferdous Ahmed
article en

Abstract

Advanced germ cell tumors (GCT) are highly curable with cisplatin-based chemotherapy; however, patients with advanced GCT are at high risk for venous thromboembolism (VTE) during treatment, and the role of thromboprophylaxis is not established. Low-dose aspirin (acetylsalicylic acid [ASA]) is inexpensive, widely available, and reduces VTE risk in orthopedic trauma, arthroplasty, and multiple myeloma settings. ASPIRE-GCT is an investigator-initiated, single-arm, prospective phase II study evaluating the 6-month VTE-free rate in patients with advanced GCT at high VTE risk who receive standard cisplatin-based chemotherapy plus ASA 81 mg daily for 26 weeks. Eligible patients are males aged 18–70 years with stage IS or higher testicular, mediastinal, or retroperitoneal GCT planned for three to four cycles of cisplatin-based chemotherapy and at least one high-risk feature: AJCC stage IIC/III or higher or Khorana score ≥2. The primary endpoint is 6-month VTE-free rate. A Simon two-stage design will enroll 13 evaluable participants in stage one and up to 31 overall. Secondary endpoints include major and clinically relevant non-major bleeding, relapse-free survival, and overall survival.Clinical trial registration www.clinicaltrials.gov identifier is NCT06866964; registered 4 March 2025; Protocol version: Version 4: 11/13/2025.

Future Oncology
Wake Forest Baptist Comprehensive Cancer Center (US)
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon